Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Pharmaceutical Design
  4. Volume 30, Issue 35
  5. Article
Volume 30, Issue 35
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Background

Previous studies have reported the benefit of statins after heart transplant (HT). However, the use of high-dose statins might be limited in some HT patients due to intolerance and interactions with immunosuppression or might not be enough to achieve low-density lipoprotein (LDL) cholesterol goals. Hyperlipidemia has been associated with coronary allograft vasculopathy. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors might be a safe and effective option in HT patients with suboptimal lipid control.

Methods

In a retrospective study, we identified HT patients in our center with LDL cholesterol >100 mg/dL, after diet modifications and up-titration of statins to maximum tolerated dose, treated with PCSK9i. The primary endpoint was LDL reduction one month after, and secondary endpoints were the development of donor-specific HLA antibodies (DSA) and the presence of coronary allograft vasculopathy or rejection.

Results

From January, 2018, to January, 2024, we identified five HT patients treated with PCSK9 inhibitors. In all cases, evolocumab was used. A significant reduction in LDL cholesterol was observed (151.6 ± 13.5 mg/dl to 72.4 ± 14.6 mg/dl; 0.04, mean reduction 75.7 ± 14.1 mg/dl), as well as in total cholesterol (231 ± 34.6 mg/dl to 152.2 ± 38.9 mg/dl; 0.01, mean reduction 78.8 ± 22.2 mg/dl). A significant increase in HDL cholesterol was not observed (45.4 ± 10.9 mg/dl to 46.2 ± 11.1 mg/dl; 0.60). One patient developed DSA five years after treatment onset. Rejection and coronary allograft vasculopathy were not observed.

Conclusion

PCSK9 inhibitors are safe and effective in reducing LDL in HT patients. However, larger studies are needed to clarify if they can reduce the development of coronary allograft vasculopathy.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpd/10.2174/0113816128315228240716183827
2024-07-29
2024-12-23

  • From This Site

    /content/journals/cpd/10.2174/0113816128315228240716183827
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. BallantyneC.M. RadovancevicB. FarmerJ.A. FrazierO.H. ChandlerL. Payton-RossC. CocanougherB. JonesP.H. YoungJ.B. GottoA.M.Jr Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations.J. Am. Coll. Cardiol.19921961315132110.1016/0735‑1097(92)90340‑S1564233
     [Google Scholar]
  2. Szyguła-JurkiewiczB. ZakliczyńskiM. SzczurekW. SkrzypekM. GąsiorM. ZembalaM. Perioperative risk factors of cardiac allograft vasculopathy in the long-term follow-up.Transplant. Proc.20164851736174110.1016/j.transproceed.2015.10.08727496482
     [Google Scholar]
  3. NoelA. GenestJ. Smashing low-density lipoprotein levels and preventing coronary allograft vasculopathy: One heart transplant patient at a time.Can. J. Cardiol.2019351171810.1016/j.cjca.2018.11.02230595177
     [Google Scholar]
  4. KobashigawaJ.A. KatznelsonS. LaksH. JohnsonJ.A. YeatmanL. WangX.M. ChiaD. TerasakiP.I. SabadA. CogertG.A. TrosianK. HamiltonM.A. MoriguchiJ.D. KawataN. HageA. DrinkwaterD.C. StevensonL.W. Effect of pravastatin on outcomes after cardiac transplantation.N. Engl. J. Med.19953331062162710.1056/NEJM1995090733310037637722
     [Google Scholar]
  5. Barge-CaballeroG. Barge-CaballeroE. Marzoa-RivasR. Paniagua-MartínM.J. Barrio-RodríguezA. Naya-LeiraC. Blanco-CanosaP. Grille-CancelaZ. Vázquez-RodríguezJ.M. Crespo-LeiroM.G. Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: Short-term and long-term efficacy and safety results.Transpl. Int.20152891034104110.1111/tri.1258525864881
     [Google Scholar]
  6. SabatineM.S. GiuglianoR.P. KeechA.C. HonarpourN. WiviottS.D. MurphyS.A. KuderJ.F. WangH. LiuT. WassermanS.M. SeverP.S. PedersenT.R. Evolocumab and clinical outcomes in patients with cardiovascular disease.N. Engl. J. Med.2017376181713172210.1056/NEJMoa161566428304224
     [Google Scholar]
  7. LiuX. BaoX. HuM. ChangH. JiaoM. ChengJ. XieL. HuangQ. LiF. LiC.Y. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.Nature2020588783969369810.1038/s41586‑020‑2911‑733177715
     [Google Scholar]
  8. XiaX. PengZ. GuH. WangM. WangG. ZhangD. Regulation of PCSK9 expression and function: Mechanisms and therapeutic implications.Front. Cardiovasc. Med.2021876403810.3389/fcvm.2021.76403834782856
     [Google Scholar]
  9. IngueneauC. HollsteinT. GrenkowitzT. RuidavetsJ.B. KassnerU. DuparcT. CombesG. PerretB. GenouxA. SchumannF. BobbertT. Steinhagen-ThiessenE. MartinezL.O. Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk.Vascul. Pharmacol.202013510680410.1016/j.vph.2020.10680432987194
     [Google Scholar]
  10. JenningsD.L. SultanL. MingovJ. ChoeJ. LatifF. RestainoS. ClerkinK. HabalM.V. ColomboP.C. YuzefpulskayaM. SayerG. UrielN. BakerW.L. PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: A systematic review and meta-analysis.Heart Fail. Rev.202228114915610.1007/s10741‑022‑10255‑535687219
     [Google Scholar]
  11. SammourY. DezorziC. AustinB.A. BorkonA.M. EverleyM.P. FendlerT.J. KhumriT.M. LawhornS.L. NassifM.E. VodnalaD. MagalskiA. KaoA.C. SperryB.W. PCSK9 inhibitors in heart transplant patients: Safety, efficacy, and angiographic correlates.J. Card. Fail.202127781281510.1016/j.cardfail.2021.02.01833753241
     [Google Scholar]
  12. MoayediY. KozuszkoS. KnowlesJ.W. ChihS. OroG. LeeR. FearonW.F. RossH.J. TeutebergJ.J. KhushK.K. Safety and efficacy of PCSK9 inhibitors after heart transplantation.Can. J. Cardiol.2019351104.e1104.e310.1016/j.cjca.2018.11.00430595172
     [Google Scholar]
  13. KühlM. BinnerC. JozwiakJ. FischerJ. HahnJ. AddasA. DinovB. GarbadeJ. HindricksG. BorgerM. Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation.PLoS One2019141e021037310.1371/journal.pone.021037330650126
     [Google Scholar]
  14. Olry de Labry LimaA. Gimeno BallesterV. Sierra SánchezJ.F. Matas HocesA. González-OutónJ. Alegre del ReyE.J. Cost-effectiveness and budget impact of treatment with evolocumab versus statins and ezetimibe for hypercholesterolemia in Spain. 2.Rev. Esp. Cardiol.201871121027103510.1016/j.rec.2018.05.00329937273
     [Google Scholar]
  15. LekuonaI. PCSK9 inhibitors: From innovation to sustainable clinical application.Rev. Esp. Cardiol.2018711299699810.1016/j.rec.2018.06.03230150140
     [Google Scholar]
  16. EstruchR. RosE. Salas-SalvadóJ. CovasM.I. CorellaD. ArósF. Gómez-GraciaE. Ruiz-GutiérrezV. FiolM. LapetraJ. Lamuela-RaventosR.M. Serra-MajemL. PintóX. BasoraJ. MuñozM.A. SorlíJ.V. MartínezJ.A. FitóM. GeaA. HernánM.A. Martínez-GonzálezM.A. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts.N. Engl. J. Med.201837825e3410.1056/NEJMoa180038929897866
     [Google Scholar]
  17. American Diabetes AssociationLifestyle Management: Standards of Medical Care in Diabetes-2018.Diabetes Care201841Suppl. 1S38S5010.2337/dc18‑S00429222375
     [Google Scholar]
  18. VisserenF.L.J. MachF. SmuldersY.M. CarballoD. KoskinasK.C. BäckM. BenetosA. BiffiA. BoavidaJ.M. CapodannoD. CosynsB. CrawfordC. DavosC.H. DesormaisI. Di AngelantonioE. FrancoO.H. HalvorsenS. HobbsF.D.R. HollanderM. JankowskaE.A. MichalM. SaccoS. SattarN. TokgozogluL. TonstadS. TsioufisK.P. van DisI. van GelderI.C. WannerC. WilliamsB. De BackerG. Regitz-ZagrosekV. AamodtA.H. AbdelhamidM. AboyansV. AlbusC. AsteggianoR. BäckM. BorgerM.A. BrotonsC. ČelutkienėJ. CifkovaR. CikesM. CosentinoF. DagresN. De BackerT. De BacquerD. DelgadoV. Den RuijterH. DendaleP. DrexelH. FalkV. FauchierL. FerenceB.A. FerrièresJ. FerriniM. FisherM. FliserD. FrasZ. GaitaD. GiampaoliS. GielenS. GrahamI. JenningsC. JorgensenT. Kautzky-WillerA. KavousiM. KoenigW. KonradiA. KotechaD. LandmesserU. LettinoM. LewisB.S. LinhartA. LøchenM-L. MakrilakisK. ManciaG. Marques-VidalP. McEvoyJ.W. McGreavyP. MerkelyB. NeubeckL. NielsenJ.C. PerkJ. PetersenS.E. PetronioA.S. PiepoliM. PogosovaN.G. PrescottE.I.B. RayK.K. ReinerZ. RichterD.J. RydénL. ShlyakhtoE. SitgesM. Sousa-UvaM. SudanoI. TiberiM. TouyzR.M. UngarA. VerschurenW.M.M. WiklundO. WoodD. ZamoranoJ.L. SmuldersY.M. CarballoD. KoskinasK.C. BäckM. BenetosA. BiffiA. BoavidaJ-M. CapodannoD. CosynsB. CrawfordC.A. DavosC.H. DesormaisI. Di AngelantonioE. Franco DuranO.H. HalvorsenS. Richard HobbsF.D. HollanderM. JankowskaE.A. MichalM. SaccoS. SattarN. TokgozogluL. TonstadS. TsioufisK.P. DisI. van GelderI.C. WannerC. WilliamsB. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.Eur. Heart J.202142343227333710.1093/eurheartj/ehab48434458905
     [Google Scholar]
  19. Mazon-RamosP. Del concepto de estatinas de alta potencia a los efectos extralipídicos de las estatinas. Revista Española de Cardiología SuplementosAmsterdmElsevier2015
     [Google Scholar]
  20. MillerL.W. SchlantR.C. KobashigawaJ. KuboS. RenlundD.G. Task force 5: Complications.J. Am. Coll. Cardiol.1993221415410.1016/0735‑1097(93)90814‑H8389776
     [Google Scholar]
  21. MorrisettJ.D. Abdel-FattahG. HoogeveenR. MitchellE. BallantyneC.M. PownallH.J. OpekunA.R. JaffeJ.S. OppermannS. KahanB.D. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients.J. Lipid Res.20024381170118010.1194/jlr.M100392‑JLR20012177161
     [Google Scholar]
  22. SchwartzG.G. StegP.G. SzarekM. BhattD.L. BittnerV.A. DiazR. EdelbergJ.M. GoodmanS.G. HanotinC. HarringtonR.A. JukemaJ.W. LecorpsG. MahaffeyK.W. MoryusefA. PordyR. QuinteroK. RoeM.T. SasielaW.J. TambyJ.F. TricociP. WhiteH.D. ZeiherA.M. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med.2018379222097210710.1056/NEJMoa180117430403574
     [Google Scholar]
  23. CostanzoM.R. CostanzoM.R. DipchandA. StarlingR. AndersonA. ChanM. DesaiS. FedsonS. FisherP. Gonzales-StawinskiG. MartinelliL. McGiffinD. ParisiF. SmithJ. TaylorD. MeiserB. WebberS. BaranD. CarboniM. DenglerT. FeldmanD. FrigerioM. KfouryA. KimD. KobashigawaJ. ShulloM. StehlikJ. TeutebergJ. UberP. ZuckermannA. HuntS. BurchM. BhatG. CanterC. ChinnockR. Crespo-LeiroM. DelgadoR. DobbelsF. GradyK. WK. LamourJ. ParryG. PatelJ. PiniD. PinneyS. TowbinJ. WolfelG. DelgadoD. EisenH. GoldbergL. HosenpudJ. JohnsonM. KeoghA. LewisC. O’ConnellJ. RogersJ. RossH. RussellS. VanhaeckeJ. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients.J. Heart Lung Transplant.201029891495610.1016/j.healun.2010.05.03420643330
     [Google Scholar]
  24. ManciniG.B.J. BakerS. BergeronJ. FitchettD. FrohlichJ. GenestJ. GuptaM. HegeleR.A. NgD. PearsonG.J. PopeJ. TashakkorA.Y. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian consensus working group update (2016).Can. J. Cardiol.2016327S35S6510.1016/j.cjca.2016.01.00327342697
     [Google Scholar]
  25. BrochK. GudeE. KarasonK. DellgrenG. RådegranG. GjesdalG. GustafssonF. EiskjærH. LommiJ. PentikäinenM. LemströmK.B. AndreassenA.K. GullestadL. Cholesterol lowering with EVOLocumab to prevent cardiac allograft vasculopathy in de-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial.Clin. Transplant.2020349e1398410.1111/ctr.1398432445429
     [Google Scholar]
  26. ChaudharyR. GargJ. ShahN. SumnerA. PCSK9 inhibitors: A new era of lipid lowering therapy.World J. Cardiol.201792769110.4330/wjc.v9.i2.7628289523
     [Google Scholar]
  27. AgarwalA. PrasadG.V.R. Post-transplant dyslipidemia: Mechanisms, diagnosis and management.World J. Transplant.20166112513410.5500/wjt.v6.i1.12527011910
     [Google Scholar]
  28. Lloyd-JonesD.M. BraunL.T. NdumeleC.E. SmithS.C.Jr SperlingL.S. ViraniS.S. BlumenthalR.S. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: A Special Report from the American Heart Association and American College of Cardiology.Circulation201913925e1162e117710.1161/CIR.000000000000063830586766
     [Google Scholar]
/content/journals/cpd/10.2174/0113816128315228240716183827
Loading
Optimization of Hypercholesterolemia Treatment after Heart Transplant: The Role of PCSK9 Inhibitors
Curr. Pharm. Des. 30, 2797 (2024); https://doi.org/10.2174/0113816128315228240716183827
/content/journals/cpd/10.2174/0113816128315228240716183827
/content/journals/cpd/10.2174/0113816128315228240716183827
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Heart transplant; cholesterol; PCSK9 inhibitors; statin, hypercholesterolemia treatment, LDL

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test